Artificial Pancreas - Medical Devices Pipeline Assessment, 2018

Artificial Pancreas - Medical Devices Pipeline Assessment, 2018

Summary

The Medical Devices sector report, Artificial Pancreas - Medical Devices Pipeline Assessment, 2018" provides an overview of Artificial Pancreas currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Artificial Pancreas pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by The team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Artificial Pancreas under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Artificial Pancreas and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry.

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Artificial Pancreas under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date.


1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Artificial Pancreas Overview 9
3 Products under Development 10
3.1 Artificial Pancreas - Pipeline Products by Stage of Development 10
3.2 Artificial Pancreas - Pipeline Products by Territory 11
3.3 Artificial Pancreas - Pipeline Products by Regulatory Path 12
3.4 Artificial Pancreas - Pipeline Products by Estimated Approval Date 13
3.5 Artificial Pancreas - Ongoing Clinical Trials 14
4 Artificial Pancreas - Pipeline Products under Development by Companies 15
4.1 Artificial Pancreas Companies - Pipeline Products by Stage of Development 15
4.2 Artificial Pancreas - Pipeline Products by Stage of Development 17
5 Artificial Pancreas Companies and Product Overview 19
5.1 Admetsys Corp Company Overview 19
5.2 Advanced Biosensors-Ohio LLC (Inactive) Company Overview 20
5.3 Animas Corp Company Overview 21
5.4 Beta Bionics Inc Company Overview 22
5.5 Beta-O2 Technologies Ltd Company Overview 27
5.6 Bigfoot Biomedical Inc Company Overview 30
5.7 BioTex Inc Company Overview 31
5.8 Boston University Company Overview 32
5.9 Cerco Medical LLC Company Overview 33
5.10 Converge Biotech, Inc. Company Overview 34
5.11 Covalor Medical, LLC Company Overview 35
5.12 De Montfort University Company Overview 36
5.13 Debiotech SA Company Overview 37
5.14 Defymed SAS Company Overview 38
5.15 Diabeloop Company Overview 39
5.16 DreaMed Diabetes Ltd Company Overview 42
5.17 EOFlow Co Ltd Company Overview 43
5.18 Giner Inc Company Overview 44
5.19 Healios Inc Company Overview 45
5.20 Imperial College London Company Overview 46
5.21 Inreda Diabetic BV Company Overview 47
5.22 Insulet Corp Company Overview 49
5.23 Kencak LLC Company Overview 50
5.24 Medtronic plc Company Overview 51
5.25 Miromatrix Medical Inc Company Overview 61
5.26 Nikkiso Co Ltd Company Overview 62
5.27 Pacific Diabetes Technologies, Inc. Company Overview 63
5.28 Pancreum, LLC Company Overview 64
5.29 PharmaCyte Biotech Inc Company Overview 65
5.30 Polytechnic University of Valencia Company Overview 66
5.31 Rensselaer Polytechnic Institute Company Overview 67
5.32 Senseonics Holdings Inc Company Overview 68
5.33 Tandem Diabetes Care Inc Company Overview 71
5.34 TecMed Inc Company Overview 74
5.35 The Alfred Mann Foundation Company Overview 75
5.36 TypeZero Technologies LLC Company Overview 76
5.37 Ultradian Diagnostics LLC Company Overview 80
5.38 Universidad Autonoma de Madrid Company Overview 81
5.39 University of California San Francisco Company Overview 82
5.40 University of California Santa Barbara Company Overview 83
5.41 University of Cambridge Company Overview 85
5.42 University of Florida Company Overview 87
5.43 University of Newcastle Company Overview 88
5.44 XERIS Pharmaceuticals Inc Company Overview 89
5.45 Yale University Company Overview 90
6 Artificial Pancreas - Recent Developments 91
6.1 Jun 28, 2018: Medtronic Launches the MiniMed 670G System Performance Guarantee for Payers and Employers 91
6.2 Jun 25, 2018: Medtronic secures CE-Mark for MiniMed insulin delivery system 91
6.3 Jun 24, 2018: MiniMed 670G System Real-World Data Show Improved Time in Range and Reduced Lows and Highs Across All Patient Groups Including a 41 Percent Time in Range Improvement for Previous MDI Patients 92
6.4 Jun 24, 2018: Insulet Presents Positive Clinical Trial Results for the Omnipod Horizon Hybrid Closed-Loop System at the American Diabetes Associations 78th Scientific Sessions 93
6.5 Jun 23, 2018: Diabeloop Insulin Delivery System May Significantly Improve Glycemic Control for People with Type 1 Diabetes 94
6.6 Jun 21, 2018: Medtronic Receives FDA Approval of New Pediatric Indication for the MiniMed 670G Hybrid Closed Loop System in Children Ages 7-13 95
6.7 Jun 19, 2018: Insulet to Unveil New Omnipod DASH System and Present Innovative Research at the American Diabetes Associations 78th Scientific Sessions 96
6.8 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 98
7 Appendix 132
7.1 Methodology 132
7.2 About GlobalData 135
7.3 Contact Us 135
7.4 Disclaimer 135

List Of Tables

1.1 List of Tables
Table 1: Artificial Pancreas - Pipeline Products by Stage of Development 11
Table 2: Artificial Pancreas - Pipeline Products by Territory 12
Table 3: Artificial Pancreas - Pipeline Products by Regulatory Path 13
Table 4: Artificial Pancreas - Pipeline Products by Estimated Approval Date 14
Table 5: Artificial Pancreas - Ongoing Clinical Trials 15
Table 6: Artificial Pancreas Companies - Pipeline Products by Stage of Development 16
Table 7: Artificial Pancreas - Pipeline Products by Stage of Development 18
Table 8: Admetsys Corp Pipeline Products & Ongoing Clinical Trials Overview 20
Table 9: Admetsys Smart Pancreas - Product Status 20
Table 10: Admetsys Smart Pancreas - Product Description 20
Table 11: Advanced Biosensors-Ohio LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 21
Table 12: Artificial Pancreas - Product Status 21
Table 13: Artificial Pancreas - Product Description 21
Table 14: Animas Corp Pipeline Products & Ongoing Clinical Trials Overview 22
Table 15: Hypoglycemia-Hyperglycemia Minimizer System - Product Status 22
Table 16: Hypoglycemia-Hyperglycemia Minimizer System - Product Description 22
Table 17: Beta Bionics Inc Pipeline Products & Ongoing Clinical Trials Overview 23
Table 18: iLet - Product Status 23
Table 19: iLet - Product Description 23
Table 20: iLet Bionic Pancreas - Insulin-only Version - Product Status 24
Table 21: iLet Bionic Pancreas - Insulin-only Version - Product Description 24
Table 22: Beta Bionics Inc - Ongoing Clinical Trials Overview 25
Table 23: iLet - Bihormonal Bionic Pancreas for the Treatment of Diabetes Post-Pancreatectomy in Children With Congenital Hyperinsulinism - A Pilot Study 26
Table 24: iLet - Feasibility of Outpatient Automated Blood Glucose Control with the Bionic Pancreas for Treatment of Cystic Fibrosis Related Diabetes 26
Table 25: iLet Bionic Pancreas - Insulin-only Version - Home-use Study to Evaluate the Efficacy of Insulin-only Configuration of iLet Bionic Pancreas System in Subjects with Type I Diabetes 27
Table 26: Beta-O2 Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 28
Table 27: Air Bio-artificial Pancreas - Product Status 28
Table 28: Air Bio-artificial Pancreas - Product Description 28
Table 29: Beta-O2 Technologies Ltd - Ongoing Clinical Trials Overview 29
Table 30: Air Bio-artificial Pancreas - An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets within the Bioartificial Pancreas Beta-Air in Patients with Type 1 Diabetes Mellitus 30
Table 31: Bigfoot Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 31
Table 32: Smartloop Automated Insulin Delivery System - Product Status 31
Table 33: Smartloop Automated Insulin Delivery System - Product Description 31
Table 34: BioTex Inc Pipeline Products & Ongoing Clinical Trials Overview 32
Table 35: Artificial Pancreas - Product Status 32
Table 36: Artificial Pancreas - Product Description 32
Table 37: Boston University Pipeline Products & Ongoing Clinical Trials Overview 33
Table 38: Bionic Pancreas - Product Status 33
Table 39: Bionic Pancreas - Product Description 33
Table 40: Cerco Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 34
Table 41: Islet Sheet - Product Status 34
Table 42: Islet Sheet - Product Description 34
Table 43: Converge Biotech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35
Table 44: Bioartificial Pancreas System - Product Status 35
Table 45: Bioartificial Pancreas System - Product Description 35
Table 46: Covalor Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 36
Table 47: Artificial Pancreas - Product Status 36
Table 48: Artificial Pancreas - Product Description 36
Table 49: De Montfort University Pipeline Products & Ongoing Clinical Trials Overview 37
Table 50: InSmart Artificial Pancreas - Product Status 37
Table 51: InSmart Artificial Pancreas - Product Description 37
Table 52: Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 38
Table 53: Next Generation Artificial Pancreas - Product Status 38
Table 54: Next Generation Artificial Pancreas - Product Description 38
Table 55: Defymed SAS Pipeline Products & Ongoing Clinical Trials Overview 39
Table 56: MAILPAN - Product Status 39
Table 57: MAILPAN - Product Description 39
Table 58: Diabeloop Pipeline Products & Ongoing Clinical Trials Overview 40
Table 59: Diabeloop Artificial Pancreas - Product Status 40
Table 60: Diabeloop Artificial Pancreas - Product Description 40
Table 61: Diabeloop - Ongoing Clinical Trials Overview 41
Table 62: Diabeloop Artificial Pancreas - Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop for Three Months at Home in Comparison with Conventional Treatment by External Insulin Pump in Patients with Type 1 Diabetes 42
Table 63: DreaMed Diabetes Ltd Pipeline Products & Ongoing Clinical Trials Overview 43
Table 64: Glucositter - Product Status 43
Table 65: Glucositter - Product Description 43
Table 66: EOFlow Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 44
Table 67: Disposable Artificial Pancreas System - Product Status 44
Table 68: Disposable Artificial Pancreas System - Product Description 44
Table 69: Giner Inc Pipeline Products & Ongoing Clinical Trials Overview 45
Table 70: BAPIOS System - Product Status 45
Table 71: BAPIOS System - Product Description 45
Table 72: Healios Inc Pipeline Products & Ongoing Clinical Trials Overview 46
Table 73: Bioengineered Pancreas - Product Status 46
Table 74: Bioengineered Pancreas - Product Description 46
Table 75: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 47
Table 76: Bio-inspired Artificial Pancreas - Product Status 47
Table 77: Bio-inspired Artificial Pancreas - Product Description 47
Table 78: Inreda Diabetic BV Pipeline Products & Ongoing Clinical Trials Overview 48
Table 79: Bi-Hormonal Artificial Pancreas - Product Status 48
Table 80: Bi-Hormonal Artificial Pancreas - Product Description 48
Table 81: Bi-Hormonal Artificial Pancreas - Lighter Version - Product Status 49
Table 82: Bi-Hormonal Artificial Pancreas - Lighter Version - Product Description 49
Table 83: Insulet Corp Pipeline Products & Ongoing Clinical Trials Overview 50
Table 84: Omnipod Horizon Hybrid Closed Loop System - Product Status 50
Table 85: Omnipod Horizon Hybrid Closed Loop System - Product Description 50
Table 86: Kencak LLC Pipeline Products & Ongoing Clinical Trials Overview 51
Table 87: BioArtificial Pancreas - Product Status 51
Table 88: BioArtificial Pancreas - Product Description 51
Table 89: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 52
Table 90: MiniMed 640G System - Product Status 52
Table 91: MiniMed 640G System - Product Description 53
Table 92: MiniMed 670G - Product Status 53
Table 93: MiniMed 670G - Product Description 53
Table 94: Third-Generation Artificial Pancreas System - Product Status 54
Table 95: Third-Generation Artificial Pancreas System - Product Description 54
Table 96: Medtronic plc - Ongoing Clinical Trials Overview 55
Table 97: MiniMed 670G - A Crossover Study Comparing Two Automated Insulin Delivery System Algorithms (PID vs. PID + Fuzzy Logic) in Adolescents and Young Adults with Type 1 Diabetes 56
Table 98: MiniMed 670G - A Safety, Tolerability and Efficacy Study of Sernovas Cell Pouch for Clinical Islet Transplantation 56
Table 99: MiniMed 670G - Clinical Startup of the 670G Closed Loop Insulin Delivery System 56
Table 100: MiniMed 670G - Effect of Hybrid Closed-loop Insulin Delivery on Glucose Counterregulation in Long Standing Type 1 Diabetes: A Proof of Concept, Mechanistic, Single-arm Clinical Trial 57

List Of Figures

1.2 List of Figures
Figure 1: Artificial Pancreas - Pipeline Products by Stage of Development 11
Figure 2: Artificial Pancreas - Pipeline Products by Territory 12
Figure 3: Artificial Pancreas - Pipeline Products by Regulatory Path 13
Figure 4: Artificial Pancreas - Pipeline Products by Estimated Approval Date 14
Figure 5: Artificial Pancreas - Ongoing Clinical Trials 15

North America Artificial Pancreas Device System Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The North America Artificial Pancreas Device System market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million

USD 3000 View Report

Global Artificial Pancreas Device System Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Artificial Pancreas Device System is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by

USD 4000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available